Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges

Abstract

Neurogenic orthostatic hypotension (nOH) is among the most debilitating nonmotor features of patients with Parkinson's disease (PD) and other synucleinopathies. Patients with PD and nOH generate more hospitalizations, make more emergency room visits, create more telephone calls/mails to doctors, and have earlier mortality than those with PD but without nOH. Overall, the health-related cost in patients with PD and OH is 2.5-fold higher compared with patients with PD without OH. Hence, developing effective therapies for nOH should be a research priority. In the last few decades, improved understanding of the pathophysiology of nOH has led to the identification of therapeutic targets and the development and approval of two drugs, midodrine and droxidopa. More effective and safer therapies, however, are still needed, particularly agents that could selectively increase blood pressure only in the standing position because supine hypertension is the main limitation of available drugs. Here we review the design and conduct of nOH clinical trials in patients with PD and other synucleinopathies, summarize the results of the most recently completed and ongoing trials, and discuss challenges, bottlenecks, and potential remedies.

Keywords

dysautonomia - orthostatic hypotension - clinical trials - design - endpoints

Publikationsverlauf

Artikel online veröffentlicht:
09. September 2020

• References

• 1 Kaufmann H, Norcliffe-Kaufmann L, Palma JA. , et al; Autonomic Disorders Consortium. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol 2017; 81 (02) 287-297
• 2 Berg D, Postuma RB, Adler CH. et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 2015; 30 (12) 1600-1611
• 3 Freeman R, Wieling W, Axelrod FB. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011; 21 (02) 69-72
• 4 Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Am J Med 2000; 108 (02) 106-111
• 5 Jonsson PV, Lipsitz LA, Kelley M, Koestner J. Hypotensive responses to common daily activities in institutionalized elderly. A potential risk for recurrent falls. Arch Intern Med 1990; 150 (07) 1518-1524
• 6 Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008; 358 (06) 615-624
• 7 Masaki KH, Schatz IJ, Burchfiel CM. et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 1998; 98 (21) 2290-2295
• 8 Kaufmann H, Biaggioni I. Autonomic failure in neurodegenerative disorders. Semin Neurol 2003; 23 (04) 351-363
• 9 Kaufmann H, Norcliffe-Kaufmann L, Palma JA. , et al; Autonomic Disorders Consortium. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol 2017; 81 (02) 287-297
• 10 Goldstein DS, Holmes C, Sharabi Y, Wu T. Survival in synucleinopathies: a prospective cohort study. Neurology 2015; 85 (18) 1554-1561
• 11 Merola A, Sawyer RP, Artusi CA. et al. Orthostatic hypotension in Parkinson disease: impact on health care utilization. Parkinsonism Relat Disord 2018; 47: 45-49
• 12 Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson disease. Handb Clin Neurol 2013; 117: 259-278
• 13 Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 2012; 46 (03) 572-580
• 14 Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract (Hoboken) 2017; 4 (03) 298-308
• 15 Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002; 58 (08) 1247-1255
• 16 Nagayama H, Yamazaki M, Ueda M. et al. Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: an autopsy case report. Mov Disord 2008; 23 (07) 1055-1057
• 17 Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010; 25 (11) 1744-1747
• 18 Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol 2014; 4 (02) 805-826
• 19 Orimo S, Oka T, Miura H. et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 73 (06) 776-777
• 20 Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 11 (06) 351-355
• 21 Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42 (3, Pt 1): 590-593
• 22 Arnold AC, Biaggioni I. Management approaches to hypertension in autonomic failure. Curr Opin Nephrol Hypertens 2012; 21 (05) 481-485
• 23 Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L. et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?. Mov Disord 2015; 30 (05) 639-645
• 24 de la Fuente-Fernández R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293 (5532): 1164-1166
• 25 U.S. Food and Drug Administration. The Voice of the Patient: A Series of Reports from FDA's Patient-Focused Drug Development initiative. 2017 . Available at: https://www.fda.gov/industry/prescription-drug-user-fee-amendments/voice-patient-series-reports-fdas-patient-focused-drug-development-initiative . Accessed January 20, 2019
• 26 Fuente Mora C, Palma JA, Kaufmann H. et al. Cerebral autoregulation and symptoms of orthostatic hypotension in familial dysautonomia. J Cereb Blood Flow Metab 2017; 37 (07) 2414-2422
• 27 Horowitz DR, Kaufmann H. Autoregulatory cerebral vasodilation occurs during orthostatic hypotension in patients with primary autonomic failure. Clin Auton Res 2001; 11 (06) 363-367
• 28 Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology 2017; 88 (01) 17-24
• 29 Palma JA, Norcliffe-Kaufmann L, Kaufmann H. An orthostatic hypotension mimic: the inebriation-like syndrome in Parkinson disease. Mov Disord 2016; 31 (04) 598-600
• 30 Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012; 87 (12) 1196-1201
• 31 Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004; 19 (11) 1306-1312
• 32 Robinson-Papp J, Sharma SK, George MC, Simpson DM. Assessment of autonomic symptoms in a medically complex, urban patient population. Clin Auton Res 2017; 27 (01) 25-29
• 33 Schrag A, Selai C, Mathias C. et al. Measuring health-related quality of life in MSA: the MSA-QoL. Mov Disord 2007; 22 (16) 2332-2338
• 34 Schrag A, Geser F, Stampfer-Kountchev M. , et al; European MSA-Study Group. Health-related quality of life in multiple system atrophy. Mov Disord 2006; 21 (06) 809-815
• 35 Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res 2012; 22 (02) 79-90
• 36 Wright RA, Kaufmann HC, Perera R. et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998; 51 (01) 120-124
• 37 Frith J, Newton JL. Validation of a questionnaire for orthostatic hypotension for routine clinical use. Geriatr Gerontol Int 2016; 16 (07) 785-790
• 38 Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont Pa) 2007; 4 (07) 28-37
• 39 Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A, Fealey RD. Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther 1986; 39 (05) 586-591
• 40 Ramirez CE, Okamoto LE, Arnold AC. et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014; 64 (06) 1235-1240
• 41 Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res 2016; 26 (04) 269-277
• 42 Norcliffe-Kaufmann L, Kaufmann H. Is ambulatory blood pressure monitoring useful in patients with chronic autonomic failure?. Clin Auton Res 2014; 24 (04) 189-192
• 43 Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine hypertension in de novo Parkinson disease. Clin Auton Res 2016; 26 (01) 15-21
• 44 Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens (Greenwich) 2002; 4 (02) 139-145
• 45 Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003; 42 (02) 136-142
• 46 Fanciulli A, Göbel G, Ndayisaba JP. et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res 2016; 26 (02) 97-105
• 47 Kaufmann H, Norcliffe-Kaufmann L, Hewitt LA, Rowse GJ, White WB. Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. J Am Soc Hypertens 2016; 10 (10) 819-826
• 48 Pickering RM, Grimbergen YA, Rigney U. et al. A meta-analysis of six prospective studies of falling in Parkinson's disease. Mov Disord 2007; 22 (13) 1892-1900
• 49 Rascol O, Perez-Lloret S, Damier P. et al. Falls in ambulatory non-demented patients with Parkinson's disease. J Neural Transm (Vienna) 2015; 122 (10) 1447-1455
• 50 van der Marck MA, Klok MP, Okun MS, Giladi N, Munneke M, Bloem BR. ; NPF Falls Task Force. Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (04) 360-369
• 51 Perez-Lloret S, Rey MV, Fabre N. et al. Do Parkinson's disease patients disclose their adverse events spontaneously?. Eur J Clin Pharmacol 2012; 68 (05) 857-865
• 52 Espay AJ, Bonato P, Nahab FB. , et al; Movement Disorders Society Task Force on Technology. Technology in Parkinson's disease: challenges and opportunities. Mov Disord 2016; 31 (09) 1272-1282
• 53 Arnerić SP, Cedarbaum JM, Khozin S. et al. Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. Nat Rev Drug Discov 2017; 16 (10) 736
• 54 Dodge HH, Zhu J, Mattek NC, Austin D, Kornfeld J, Kaye JA. Use of high-frequency in-home monitoring data may reduce sample sizes needed in clinical trials. PLoS One 2015; 10 (09) e0138095
• 55 Evans SR. Clinical trial structures. J Exp Stroke Transl Med 2010; 3 (01) 8-18
• 56 Kaufmann H, Saadia D, Voustianiouk A. et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003; 108 (06) 724-728
• 57 Shibao C, Raj SR, Gamboa A. et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 2007; 50 (01) 47-53
• 58 Okamoto LE, Shibao C, Gamboa A. et al. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. Hypertension 2012; 59 (03) 650-656
• 59 Shibao C, Gamboa A, Diedrich A. et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension 2007; 50 (01) 54-61
• 60 Okamoto LE, Diedrich A, Baudenbacher FJ. et al. Efficacy of servo-controlled splanchnic venous compression in the treatment of orthostatic hypotension: a randomized comparison with midodrine. Hypertension 2016; 68 (02) 418-426
• 61 Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. ; Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015; 65 (01) 101-107
• 62 Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy--randomized trials in individual patients. N Engl J Med 1986; 314 (14) 889-892
• 63 Guyatt GH, Heyting A, Jaeschke R, Keller J, Adachi JD, Roberts RS. N of 1 randomized trials for investigating new drugs. Control Clin Trials 1990; 11 (02) 88-100
• 64 Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Per Med 2011; 8 (02) 161-173
• 65 Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988; 38 (06) 951-956
• 66 Kaufmann H, Freeman R, Biaggioni I. , et al; NOH301 Investigators. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014; 83 (04) 328-335
• 67 Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and reduced falls in a trial of Parkinson disease patients with neurogenic orthostatic hypotension. Clin Neuropharmacol 2016; 39 (05) 220-226
• 68 Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014; 4 (01) 57-65
• 69 Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord 2015; 30 (05) 646-654
• 70 Close S, Smaldone A, Fennoy I, Reame N, Grey M. Using information technology and social networking for recruitment of research participants: experience from an exploratory study of pediatric Klinefelter syndrome. J Med Internet Res 2013; 15 (03) e48
• 71 Jordan J, Shannon JR, Black BK. et al. The pressor response to water drinking in humans : a sympathetic reflex?. Circulation 2000; 101 (05) 504-509
• 72 May M, Jordan J. The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol 2011; 300 (01) R40-R46
• 73 Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007; 22 (11) 1543-1549
• 74 Fanciulli A, Goebel G, Metzler B. et al. Elastic abdominal binders attenuate orthostatic hypotension in Parkinson's disease. Mov Disord Clin Pract (Hoboken) 2015; 3 (02) 156-160
• 75 Schreglmann SR, Büchele F, Sommerauer M. et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Eur J Neurol 2017; 24 (04) 545-551
• 76 Jankovic J, Gilden JL, Hiner BC. et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95 (01) 38-48
• 77 Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. ; Midodrine Study Group. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA 1997; 277 (13) 1046-1051
• 78 McTavish D, Goa KL. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989; 38 (05) 757-777
• 79 Schirger A, Sheps SG, Thomas JE, Fealey RD. Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. Mayo Clin Proc 1981; 56 (07) 429-433
• 80 Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther 2015; 13 (08) 875-891
• 81 Kaufmann H. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?. Clin Auton Res 2017; 27 (Suppl. 01) 1-3
• 82 Gupta F, Karabin B, Mehdirad A. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension. Clin Auton Res 2017; 27 (Suppl. 01) 15-16
• 83 Vernino S, Claassen D. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus. Clin Auton Res 2017; 27 (Suppl. 01) 33-34
• 84 Kremens D, Lew M, Claassen D, Goodman BP. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease. Clin Auton Res 2017; 27 (Suppl. 01) 29-31
• 85 Mehdirad A, Karabin B, Gupta F. Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension. Clin Auton Res 2017; 27 (Suppl. 01) 25-27
• 86 Claassen D, Lew M. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. Clin Auton Res 2017; 27 (Suppl. 01) 13-14
• 87 Goodman BP, Claassen D, Mehdirad A. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease. Clin Auton Res 2017; 27 (Suppl. 01) 17-19
• 88 Goodman BP, Gupta F. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy. Clin Auton Res 2017; 27 (Suppl. 01) 21-23
• 89 Gupta F, Kremens D, Vernino S, Karabin B. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease. Clin Auton Res 2017; 27 (Suppl. 01) 9-11
• 90 Bartholini J, Constantinidis J, Puig M, Tissot R, Pletscher A. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther 1975; 193 (02) 523-532
• 91 Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol 2017; 17 (01) 90
• 92 Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res 2016; 26 (03) 171-180
• 93 Singer W, Sandroni P, Opfer-Gehrking TL. et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006; 63 (04) 513-518
• 94 Byun JI, Moon J, Kim DY. et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology 2017; 89 (10) 1078-1086
• 95 Hauser AS, Chavali S, Masuho I. et al. Pharmacogenomics of GPCR drug targets. Cell 2018; 172 (1-2): 41-54.e19
• 96 Hoeldtke RD, Cilmi KM, Mattis-Graves K. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension. Clin Pharmacol Ther 1984; 36 (03) 302-306
• 97 Kaufmann H, Oribe E, Yahr MD. Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm Park Dis Dement Sect 1991; 3 (02) 143-148
• 98 Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999; 53 (09) 2151-2157
• 99 Mathias CJ, Senard JM, Braune S. et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001; 11 (04) 235-242